Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. Many women experience hypotrichosis as they age, finding that their eyelashes become thinner and lighter in appearance. Latisse® is a solution that is applied to the lash line once a day. This prescription treatment stimulates the growth of eyelashes, making them longer, thicker and darker.

Latisse® is the first and only FDA-approved prescription treatment for inadequate or not enough eyelashes. With an easy to use applicator, Latisse® is applied once-nightly to the base of the upper eyelashes, as instructed by Dr. Roth. Results appear gradually, some patients see results in as little as 4 weeks with full results achieved in 16 weeks.

Eyelash growth is caused by the active ingredient in Latisse®, bimatoprost. This agent is believed to affect the growth phase of the eyelash hair cycle in two ways: first by increasing the length of the growth period, and second by increasing the number of hairs grown.

Latisse® was created by Allergen, a leader in pharmaceuticals with over 60 years experience in eye care. Originally introduced as a medicated eye drop to treat elevated intraocular pressure, the medication had the unintended side effect of growing longer, fuller and darker eyelashes in patients. Clinical trails were performed to study the medication’s active ingredient, leading to FDA approval in 2008.

A comprehensive eye exam and evaluation is required before Dr. Roth will prescribe Latisse®. In some cases, your insurance company may cover the eye exam.

Schedule a consultation with Dr. Roth today to learn more about Latisse® and find out if you are a candidate.